TORONTO and DALLAS, Jan. 30,
2025 /CNW/ - Perimeter Medical Imaging AI, Inc.
(TSXV: PINK) (OTC: PYNKF) ("Perimeter" or the "Company"), a
commercial-stage medical technology company, today announced that
Bristol Investor Relations will host an investor webcast
Thursday, February 6, 2025 at
2:00 PM ET.
During the webcast, Adrian
Mendes, CEO, Andrew Berkeley,
CIO, and Sara Brien, CFO, will
conduct a presentation that will cover key areas of Perimeter 's
business. After the formal presentation, investors will have an
opportunity to ask relevant questions through an interactive
Q&A portal. To listen to the live webcast and/or to ask
questions during the live event, please pre-register at the
following link:
https://us02web.zoom.us/webinar/register/WN_2VupRCLTS3GAlYyO1m6ToQ
An archived version of the webcast and presentation will be made
available as soon as is practicable on the Company's website under
"News/Events" in the Investors Section.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and
Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) is a company driven to
transform cancer surgery with ultra-high-resolution, real-time,
advanced imaging tools to address areas of high unmet medical need.
Available across the U.S., our FDA-cleared Perimeter S-Series OCT
system provides real-time, cross-sectional visualization of excised
tissues at the cellular level. The breakthrough-device-designated
investigational Perimeter B-Series OCT with ImgAssist AI represents
our next-generation artificial intelligence technology that has
recently been evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million awarded by the
Cancer Prevention and Research Institute of Texas. The
company's ticker symbol "PINK" is a reference to the pink ribbons
used during Breast Cancer Awareness Month.
Perimeter B-Series OCT is limited by U.S. law to
investigational use and not available for sale in the
United States. Perimeter S-Series
OCT has 510(k) clearance under a general indication and has not
been evaluated by the U.S. FDA specifically for use in breast
tissue, breast cancer, other types of cancer, margin evaluation,
and reducing re-excision rates. The safety and effectiveness of
these uses has not been established. For more information, please
visit www.perimetermed.com/disclosures.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
"forward-looking information" within the meaning of applicable
Canadian securities legislation. In this news release, words such
as "may," "would," "could," "will," "likely," "believe," "expect,"
"anticipate," "intend," "plan," "estimate," and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management's
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, statements regarding the timing of the annual meeting,
are forward-looking information. Forward-looking statements should
not be read as guarantees of future performance or results, and
will not necessarily be accurate indications of whether, or the
times at or by which, any particular result will be achieved. No
assurance can be given that any events anticipated by the
forward-looking information will transpire or occur.
Forward-looking information is based on information available at
the time and/or management's good-faith belief with respect to
future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter's control. Such forward-looking
statements reflect Perimeter's current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter's
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter's
Management Discussion and Analysis for the year ended December
31, 2023, which is available on Perimeter's SEDAR+ profile
at https://www.sedarplus.ca, and could cause actual events or
results to differ materially from those projected in any
forward-looking statements. Perimeter does not intend, nor does
Perimeter undertake any obligation, to update or revise any
forward-looking information contained in this news release to
reflect subsequent information, events, or circumstances or
otherwise, except if required by applicable laws.
CONTACTS:
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: skilmer@perimetermed.com
Glen Akselrod
Bristol Capital
Telephone: 905-326-1888 ext 1
Email: glen@bristolir.com
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-to-participate-in-investor-webinar-on-february-6th-302364841.html
SOURCE Perimeter Medical Imaging AI Inc.
